Endocrine Abstracts

Background: Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1-RA) whose role as a second-line treatment for patients with type 2 diabetes (T2D) has significantly increased. It has demonstrated cardiovascular safety and superiority in terms of glycaemic control and weight loss, compared to other GLP-1-RAs. The most common side effects are mild gastrointestinal, but it may also cause renal failure secondary to dehydration and an increased risk of diabetic retinopa...

Objectives: Evaluate the impact of the therapy with GLP-1 analogues (exenatide) toguether with basal insulin in glycemic control and weight of patients with type 2 diabetes mellitus poorly controlled.Materials and methods: We analyzed 37 patients with type 2 diabetes with poor glycemic control and obesity, treatment with exenatide and basal insulin. As pre-treatment 56.7% of our patients were with basal insulin, 10.8% with insulin mixtures and 32.4% with...